Christoph Rader

List of Publications by Citations

116 papers	4,858 citations	37 h-index	67 g-index
121 ext. papers	5,919 ext. citations	6.7 avg, IF	5.9 L-index

#	Paper	IF	Citations
116	SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. *Nature Communications*, **2020**, 11, 6013	17.4	450
115	Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. *Clinical Cancer Research*, **2013**, 19, 3153-64	12.9	330
114	The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. *Cancer Immunology Research*, **2015**, 3, 125-35	12.5	294
113	The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. *Blood*, **2010**, 116, 4532-41	2.2	200
112	Phage display of combinatorial antibody libraries. *Current Opinion in Biotechnology*, **1997**, 8, 503-8	11.4	191
111	The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. *Journal of Neuroscience*, **2005**, 25, 808-22	6.6	188
110	Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. *Clinical Cancer Research*, **2008**, 14, 396-404	12.9	173
109	Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. *Cancer Cell*, **2019**, 35, 489-503.e8	24.3	123
108	Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. *Cancer Immunology Research*, **2015**, 3, 206-16	12.5	112
107	Implications of the HIV-1 Rev dimer structure at 3.2 A resolution for multimeric binding to the Rev response element. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 5810-4	11.5	106
106	Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson disease Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications. *European Polymer Journal*, **2017**, 88, 524-552	5.2	93
105	The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. *Journal of Biological Chemistry*, **2000**, 275, 13668-76	5.4	88
104	Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. *Journal of Molecular Biology*, **2003**, 325, 325-35	6.5	87
103	Molecularly defined antibody conjugation through a selenocysteine interface. *Biochemistry*, **2009**, 48, 12047-57	3.2	86
102	Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 5396-400	11.5	79
101	Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 8293-8	11.5	75
100	A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. *Journal of Molecular Biology*, **2003**, 332, 889-99	6.5	71

99	Improving the serum stability of site-specific antibody conjugates with sulfone linkers. *Bioconjugate Chemistry*, **2014**, 25, 1402-7	6.3	70
98	From rabbit antibody repertoires to rabbit monoclonal antibodies. *Experimental and Molecular Medicine*, **2017**, 49, e305	12.8	69
97	An engineered selenocysteine defines a unique class of antibody derivatives. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 12451-6	11.5	68
96	Strain Prioritization and Genome Mining for Enediyne Natural Products. *MBio*, **2016**, 7,	7.8	66
95	Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. *PLoS ONE*, **2011**, 6, e21018	3.7	63
94	Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. *FASEB Journal*, **2002**, 16, 2000-2	0.9	62
93	A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. *Blood*, **2018**, 132, 521-532	2.2	56
92	DARTs take aim at BiTEs. *Blood*, **2011**, 117, 4403-4	2.2	56
91	IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. *PLoS ONE*, **2015**, 10, e0133152	3.7	56
90	Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates. *Nature Communications*, **2017**, 8, 1112	17.4	52
89	Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. *Journal of Biological Chemistry*, **2000**, 275, 36073-8	5.4	51
88	Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. *Cancer Research*, **2005**, 65, 972-81	10.1	51
87	Targeting malignant B cells with an immunotoxin against ROR1. *MAbs*, **2012**, 4, 349-61	6.6	50
86	Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. *Cancer Cell*, **2021**, 39, 193-208.e10	24.3	50
85	Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. *Journal of Biological Chemistry*, **2003**, 278, 47812-9	5.4	43
84	Isolation of human prostate cancer cell reactive antibodies using phage display technology. *Journal of Immunological Methods*, **2004**, 291, 137-51	2.5	43
83	Mining human antibody repertoires. *MAbs*, **2010**, 2, 365-78	6.6	40
82	Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. *International Journal of Cancer*, **2006**, 119, 1194-207	7.5	39

81	Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices. *Journal of Medicinal Chemistry*, **2004**, 47, 5630-40	8.3	38
80	Genome Mining of Micromonospora yangpuensis DSM 45577 as a Producer of an Anthraquinone-Fused Enediyne. *Organic Letters*, **2017**, 19, 6192-6195	6.2	37
79	Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues. *Bioconjugate Chemistry*, **2015**, 26, 2243-8	6.3	37
78	Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E5467-E5476	11.5	37
77	Chemically programmed antibodies. *Trends in Biotechnology*, **2014**, 32, 186-97	15.1	36
76	Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. *Journal of Immunological Methods*, **2004**, 288, 149-64	2.5	36
75	Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. *PLoS ONE*, **2012**, 7, e52655	3.7	36
74	Antibody conjugation via one and two C-terminal selenocysteines. *Methods*, **2014**, 65, 133-8	4.6	34
73	Bispecific antibodies in cancer immunotherapy. *Current Opinion in Biotechnology*, **2020**, 65, 9-16	11.4	32
72	Application of strain-promoted azide-alkyne cycloaddition and tetrazine ligation to targeted Fc-drug conjugates. *Bioconjugate Chemistry*, **2012**, 23, 2007-13	6.3	31
71	Chimeric rabbit/human Fab and IgG specific for members of the Nogo-66 receptor family selected for species cross-reactivity with an improved phage display vector. *Journal of Immunological Methods*, **2007**, 318, 75-87	2.5	30
70	Antibody libraries in drug and target discovery. *Drug Discovery Today*, **2001**, 6, 36-43	8.8	30
69	Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility. *Journal of Molecular Biology*, **2017**, 429, 2954-2973	6.5	29
68	CAR T cells targeting β integrin are effective against advanced cancer in preclinical models. *Advances in Cell and Gene Therapy*, **2018**, 1, e11	1.2	28
67	Chemically Programmed Bispecific Antibodies in Diabody Format. *Journal of Biological Chemistry*, **2016**, 291, 19661-73	5.4	26
66	Generation and characterization of a chimeric rabbit/human Fab for co-crystallization of HIV-1 Rev. *Journal of Molecular Biology*, **2010**, 397, 697-708	6.5	24
65	Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. *Journal of Molecular Biology*, **2008**, 384, 1143-56	6.5	24
64	Chemically programmed bispecific antibodies that recruit and activate T cells. *Journal of Biological Chemistry*, **2012**, 287, 28206-14	5.4	22

63	Generation and selection of rabbit antibody libraries by phage display. *Methods in Molecular Biology* , **2009**, 525, 101-28, xiv	1.4	22
62	Comparative Studies of the Biosynthetic Gene Clusters for Anthraquinone-Fused Enediynes Shedding Light into the Tailoring Steps of Tiancimycin Biosynthesis. *Organic Letters*, **2018**, 20, 5918-5921	6.2	22
61	Catalytic antibodies as magic bullets. *Chemistry - A European Journal*, **2000**, 6, 2091-5	4.8	21
60	Chimeric Antigen Receptor Library Screening Using a Novel NF-Β/NFAT Reporter Cell Platform. *Molecular Therapy*, **2019**, 27, 287-299	11.7	21
59	Stable and Potent Selenomab-Drug Conjugates. *Cell Chemical Biology*, **2017**, 24, 433-442.e6	8.2	20
58	Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2. *PLoS Pathogens*, **2021**, 17, e1009501	7.6	20
57	Dual-mechanistic antibody-drug conjugate site-specific selenocysteine/cysteine conjugation. *Antibody Therapeutics*, **2019**, 2, 71-78	5.8	19
56	Recognition of antigen-specific B-cell receptors from chronic lymphocytic leukemia patients by synthetic antigen surrogates. *Chemistry and Biology*, **2014**, 21, 1670-9		19
55	E. coli expression and purification of Fab antibody fragments. *Current Protocols in Protein Science*, **2009**, Chapter 6, Unit 6.10	3.1	19
54	Generation and validation of structurally defined antibody-siRNA conjugates. *Nucleic Acids Research* , **2020**, 48, 5281-5293	20.1	18
53	Overview on concepts and applications of Fab antibody fragments. *Current Protocols in Protein Science*, **2009**, Chapter 6, Unit 6.9	3.1	18
52	A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. *Blood*, **2009**, 114, 4494-502	2.2	18
51	Assessment of reagents for selenocysteine conjugation and the stability of selenocysteine adducts. *Organic and Biomolecular Chemistry*, **2016**, 14, 5141-7	3.9	18
50	ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. *Blood*, **2019**, 134, 432-444	2.2	17
49	Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody-Drug Conjugates. *Bioconjugate Chemistry*, **2019**, 30, 2889-2896	6.3	16
48	Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2 **2020**,		16
47	ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. *Experimental Hematology*, **2015**, 43, 770-4.e2	3.1	15
46	Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications. *Journal of Biological Chemistry*, **2020**, 295, 5995-6006	5.4	14

45	Chemical biology: How to minimalize antibodies. *Nature*, **2015**, 518, 38-9	50.4	14
44	Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation. *Bioconjugate Chemistry*, **2016**, 27, 2271-2275	6.3	14
43	Lipid-directed vinculin dimerization. *Biochemistry*, **2015**, 54, 2758-68	3.2	13
42	Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues. *Cell Chemical Biology*, **2019**, 26, 1229-1239.e9	8.2	13
41	Rabbit models of human diseases for diagnostics and therapeutics development. *Developmental and Comparative Immunology*, **2019**, 92, 99-104	3.2	12
40	Chemically Programmable and Switchable CAR-T Therapy. *Angewandte Chemie - International Edition*, **2020**, 59, 12178-12185	16.4	11
39	Harnessing the fc□receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. *Cancer Research*, **2014**, 74, 7510-7520	10.1	11
38	Antibody-based cancer therapy. *Oncogene*, **2021**, 40, 3655-3664	9.2	11
37	Targeting Stereotyped B Cell Receptors from Chronic Lymphocytic Leukemia Patients with Synthetic Antigen Surrogates. *Journal of Biological Chemistry*, **2016**, 291, 7558-70	5.4	11
36	Challenges and Opportunities to Develop Enediyne Natural Products as Payloads for Antibody-Drug Conjugates. *Antibody Therapeutics*, **2021**, 4, 1-15	5.8	11
35	Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5785-8	2.9	9
34	Cloning, expression, and purification of monoclonal antibodies in scFv-Fc format. *Methods in Molecular Biology*, **2012**, 901, 209-32	1.4	7
33	Characterization of TnmH as an -Methyltransferase Revealing Insights into Tiancimycin Biosynthesis and Enabling a Biocatalytic Strategy To Prepare Antibody-Tiancimycin Conjugates. *Journal of Medicinal Chemistry*, **2020**, 63, 8432-8441	8.3	7
32	Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1. *Frontiers in Immunology*, **2019**, 10, 1994	8.4	6
31	Engineered production of cancer targeting peptide (CTP)-containing C-1027 in Streptomyces globisporus and biological evaluation. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 3887-3892	3.4	6
30	An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies. *Methods*, **2019**, 154, 70-76	4.6	6
29	Generation of human Fab libraries for phage display. *Methods in Molecular Biology*, **2012**, 901, 53-79	1.4	6
28	Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies. *Cancer Immunology Research*, **2018**, 6, 1008-1013	12.5	5

27	Utilization of Selenocysteine for Site-Specific Antibody Conjugation. *Methods in Molecular Biology*, **2017**, 1575, 145-164	1.4	5
26	Engineering Dual Variable Domains for the Generation of Site-Specific Antibody-Drug Conjugates. *Methods in Molecular Biology*, **2019**, 2033, 39-52	1.4	5
25	Adoptive T□cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. *Molecular Therapy - Oncolytics*, **2021**, 20, 387-398	6.4	5
24	Site-Specific Antibody-Drug Conjugates in Triple Variable Domain Fab Format. *Biomolecules*, **2020**, 10,	5.9	4
23	Chimeric rabbit/human Fab antibodies against the hepatitis Be-antigen and their potential applications in assays, characterization, and therapy. *Journal of Biological Chemistry*, **2017**, 292, 16760-16772	5.4	4
22	Discovery of ammosesters by mining the Streptomyces uncialis DCA2648 genome revealing new insight into ammosamide biosynthesis. *Journal of Industrial Microbiology and Biotechnology*, **2021**, 48,	4.2	4
21	Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia. *Leukemia*, **2021**, 35, 2581-2591	10.7	4
20	BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. *Blood*, **2021**, 138, 1843-1854	2.2	3
19	Selection of apoptotic cell specific human antibodies from adult bone marrow. *PLoS ONE*, **2014**, 9, e95999	3.7	2
18	Selection of human Fab libraries by phage display. *Methods in Molecular Biology*, **2012**, 901, 81-99	1.4	2
17	A new immunochemical strategy for triple-negative breast cancer therapy. *Scientific Reports*, **2021**, 11, 14875	4.9	2
16	The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. *Blood Advances*, **2021**, 5, 3152-3162	7.8	2
15	Redirecting cytotoxic T cells with chemically programmed antibodies. *Bioorganic and Medicinal Chemistry*, **2020**, 28, 115834	3.4	1
14	Chemically Programmable and Switchable CAR-T Therapy. *Angewandte Chemie*, **2020**, 132, 12276-12283	3.6	1
13	Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia. *Blood*, **2013**, 122, 4168-4168	2.2	1
12	An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation. *Biochemistry*, **2021**, 60, 1080-1087	3.2	1
11	A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries. *Journal of Molecular Biology*, **2018**, 430, 4387-4400	6.5	1
10	Monoclonal Antibodies in Cancer Therapy **2007**, 453-484		1

9	Soluble BAFF Is Elevated Following Allogeneic SCT but Is Not an Early Predictor for the Development of cGVHD.. *Blood*, **2007**, 110, 167-167	2.2	0
8	A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib. *Blood*, **2019**, 134, 2861-2861	2.2	0
7	Chemical Assembly of Antibody-Drug Conjugates. *Milestones in Drug Therapy*, **2017**, 1-28		
6	Carlos F. Barbas III (1964-2014): Visionary at the interface of chemistry and biology. *ACS Chemical Biology*, **2014**, 9, 1645-6	4.9	
5	Defining the Biochemical Role of Sialic Acid-Binding Immunoglobulin-like Lectin-6 in Adhesion and Migration in Chronic Lymphocytic Leukemia. *Blood*, **2021**, 138, 2623-2623	2.2	
4	Simultaneous Silencing of Two Independent Signaling Pathways Essential for Angiogenesis Using Bispecific, Tetravalent Intra-Diabodies.. *Blood*, **2004**, 104, 5284-5284	2.2	
3	Monoclonal Antibody Therapy for Cancer **2011**, 59-83		
2	Generation of a Platform for Identification of CLL Specific Cell Surface Proteins Targeted by Anti-Tumor Antibodies in Patient Sera After Allogeneic Hematopoietic Cell Transplantion. *Blood*, **2012**, 120, 1349-1349	2.2	
1	ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia. *Leukemia Research*, **2022**, 118, 106872	2.7	